PREVIOUS
✖
Access To Medicine Foundation 2024 Index Report
December 2 , 2024
21 days
176
0
- It is evaluating 20 leading pharmaceutical companies on their efforts to expand access to their products in low- and middle-income countries (LMIC).
- Overall industry performance has declined since the 2022 Index.
- 61 per cent of the products assessed still lacking access strategies for low-income countries, compared with 65 per cent in the 2022 Index.
- Only 43 per cent of clinical trials take place in the 113 LMICs.
Leave a Reply
Your Comment is awaiting moderation.